Prophylactic and therapeutic vaccines against human papilloma virus

• Published in: HNO Vol. 58; no. 8; p. 778
• Main Authors: Albers, A E, Hoffmann, T K, Klussmann, J P, Kaufmann, A M
• Format: Journal Article
• Language: German
• Published: Germany 01.08.2010
• Subjects: Adolescent; Adult; Antibody Formation - immunology; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - immunology; Carcinoma, Squamous Cell - prevention & control; Child; Condylomata Acuminata - drug therapy; Condylomata Acuminata - immunology; Condylomata Acuminata - prevention & control; Female; Human papillomavirus 11 - immunology; Human papillomavirus 16 - immunology; Human papillomavirus 18 - immunology; Human papillomavirus 6 - immunology; Humans; Immunity, Cellular - immunology; Laryngeal Neoplasms - drug therapy; Laryngeal Neoplasms - immunology; Laryngeal Neoplasms - prevention & control; Otorhinolaryngologic Neoplasms - drug therapy; Otorhinolaryngologic Neoplasms - immunology; Otorhinolaryngologic Neoplasms - prevention & control; Papilloma - drug therapy; Papilloma - immunology; Papilloma - prevention & control; Papillomavirus Vaccines - therapeutic use; Risk Factors; Treatment Outcome; Young Adult
• ISSN: 1433-0458
• DOI: 10.1007/s00106-010-2118-6

Infection with human papilloma virus (HPV) has been identified as the cause of recurrent papillomatosis and of a subgroup of squamous cell carcinomas of the head and neck. A change in prevalence of these lesions, especially for oropharyngeal carcinoma, can be expected as a consequence of the introduction of prophylactic HPV vaccines for young women, targeting the most frequent high- and low-risk HPV subtypes. Vaccination for the major low-risk HPV types has proven to be highly effective against genital warts and activity against papillomatosis can be expected. The possibilities of prophylactic HPV vaccination as well as new developments and the rationale for therapeutic vaccines are discussed on the basis of the current literature.